2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2334 A dual-targeting SEMA4A-BCMA CAR T cell platform to treat multiple myeloma heterogeneity and prevent target antigen escape

Silvia Marino, PhD, Annamaria Cesarano, MS2, Michelle Saetersmoen, PhD3, Francesco Di Meo, PhD4, Francesca Albano, PhD5, Emaan Niaz, N/A6, Doris K. Hansen, MD7, Jorge Mansilla-Soto, PhD8, Fabiana Perna, MD, PhD9
1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) induces clinical remission in patients with relapsed and/or refractory multiple myeloma (RRMM). However, most patients eventually relapse. Heterogeneous BCMA expression results in preferential elimination of BCMAhigh clones while promoting the outgrowth of BCMAlow/null clones. Therefore, targeting alternative antigens, either alone or in combination with BCMA, may prevent antigen escape and improve the durability of CAR T-cell therapy. Several dual-target CAR T-cell therapies with different architectures targeting BCMA together with antigens such as CD19 or GPRC5D have shown promising clinical activity.

We recently demonstrated that relapse post BCMA CAR T-cell therapy is associated with reduced BCMA antigen density on MM cells and developed SEMA4A-directed CAR T cells that outperform BCMA CAR T cells under conditions of low BCMA expression. We showed that SEMA4A is highly and frequently expressed in MM patients, exhibits an expression pattern independent of BCMA, and displays a more favorable normal tissue expression profile than most antigens currently targeted in MM immunotherapy (Di Meo, Albano et al., Cancer Cell, 2025).

Here, we developed and screened a panel of dual-specific bicistronic SEMA4A-BCMA CAR T cells to identify a lead platform. 

We initially generated four bicistronic CAR constructs incorporating high-affinity BCMA and SEMA4A single-chain variable fragments (scFvs), reciprocal CD28 and 4-1BB co-stimulatory, and CD3ζ signaling domains (Ag1-41BBζ/Ag2-CD28ζ, Ag1-CD28ζ/Ag2-41BBζ, Ag2-41BBζ/Ag1-CD28ζ, and Ag2-CD28ζ/Ag1-41BBζ). An EF1α-based lentiviral vector was used to deliver the two CAR transgenes, separated by a P2A peptide to enable co-expression. CAR surface expression on engineered T cells was assessed by flow-cytometry using recombinant human BCMA and SEMA4A proteins 96 hours after transduction. CAR T cells were screened in vitro based on CAR expression levels and cytotoxic activity against MM cell lines (H929, U266, and AMO1) expressing variable BCMA and SEMA4A levels.
To evaluate efficacy in vivo, we established two mouse models designed to recapitulate the antigen heterogeneity observed in bone marrow samples from RRMM patients.
In the first model, immunodeficient NSG mice were injected with a heterogeneous population of firefly luciferase-labeled (FFLuc+) H929 cells consisting of BCMA+/SEMA4A+ (60%), BCMAKO/SEMA4A+ (20%), and BCMA+/SEMA4AKO (20%) cells generated using CRISPR/Cas9-mediated gene editing. These proportions reflect the antigen distribution we observed in a cohort of 11 RRMM patients, in whom most MM cells co-expressed BCMA and SEMA4A, while smaller subclones expressed only one of the two antigens and therefore represented potential mechanisms of antigen escape.
In the second model, we specifically evaluated the elimination of FFLuc-labeled BCMAKO/SEMA4A+ cells, which were co-injected with unlabeled BCMA+/SEMA4A+ H929 cells at a 20:80 ratio.
Seven days after tumor inoculation, mice received a single infusion of BCMA CAR T cells, dual-target SEMA4A-BCMA CAR T cells, or untransduced T cells as controls.

Our screening revealed that CAR surface expression was strongly influenced by vector configuration. Constructs with SEMA4A CAR positioned first, SEMA4A-28ζ/BCMA-BBζ (BIC2) and SEMA4A-BBζ/BCMA-28ζ (BIC3), produced balanced expression of both CARs. Among these, BIC3 achieved the highest expression of both receptors (up to 30%) and was selected for further evaluation.
Dual-target BIC3 CAR T cells exhibited potent cytotoxic activity against MM cell lines endogenously expressing variable levels of BCMA and SEMA4A, as well as BCMAKO/SEMA4A+ H929 cells resistant to BCMA CAR T cells.
In vivo, both BCMA monospecific and dual-target BIC3 CAR T cells, controlled tumor growth in NSG mice bearing heterogeneous BCMA+/SEMA4A+, BCMAKO/SEMA4A+, and BCMA+/SEMA4AKO tumors at the time when control animals reached study endpoint. In the second model, dual-target BIC3 CAR T cells demonstrated superior activity compared with BCMA CAR T cells in eliminating FFLuc+ BCMAKO/SEMA4A+ cells.

Overall, our study identifies SEMA4A-BBζ/BCMA-28ζ (BIC3) bicistronic CAR T-cell platform as the lead candidate, demonstrating potent activity against both BCMAhigh and BCMAlow/null MM cells. These findings provide the preclinical rationale for advancing this dual-target BCMA-SEMA4A lentiviral CAR T-cell platform into a Phase I clinical trial.
Silvia Marino, PhD: No relevant conflicts of interest to declare.